More trial evidence supports drug tenecteplase for acute stroke treatment
UC expert's comments at international conference featured in TCT MD
Research data presented at the European Stroke Organisation Conference last week suggests clot-busting drug tenecteplase (TNK) is an effective, if not preferred, alternative to the current standard, alteplase, to treat patients with acute ischemic stroke who require a medication to break up blood clots.
TCT MD highlighted some of the trials presented at the conference, as well as expert commentary from attendees.
Trials of alteplase, also called tPA, were pioneered at the University of Cincinnati in the late 1980s, representing the first proven treatment for ischemic stroke. TNK is a more recently developed clot-busting drug that can be administered in a single IV injection within seconds.
Some researchers at the conference said the new trial data suggests TNK should be the first choice when a medication is needed to break up a blood clot.
Commenting on a TNK trial conducted in China, Eva Mistry, MBBS, told TCT MD the encouraging results are most applicable to patients who do not have timely access to mechanical thrombectomy, a minimally invasive procedure for acute ischemic stroke patients that uses a catheter to remove a blood clot from a blood vessel in the brain, which restores blood flow.
“But I think it’s an important trial that shows us that TNK helps lyse big clots. Mechanistically, that makes sense,” said Mistry, a UC Gardner Neuroscience Institute physician researcher and assistant professor in the Department of Neurology and Rehabilitation medicine in UC’s College of Medicine.
“But I would not delay transfer for this,” Mistry continued. “I wouldn’t do anything differently other than making a case that, ‘Well, I can now give them TNK in addition to doing everything else I was to get them ready for thrombectomy.’”
Featured photo at top of illustration of brain with stroke symptoms. Photo/PeterSchreiber.media/iStock.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.